AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28950849
Drug: Bacteriophage (Pyo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacteriophage (Pyo bacteriophage) solution for 7 days
Trial: 28950849
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution for 7 days
Trial: 28950849
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment according to sensitivity pattern for 7 days
Trial: 21590473
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine 0.2 mg
Trial: 18356448
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg I/kg of body weight
Trial: 18356448
Drug: 525 mg
RxNorm normalized name: psyllium 525 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 525 mg I/kg of body weight
Trial: 18356448
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg I/kg of body weight
Trial: 14700556
Drug: Pegvisomant (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegvisomant (median dose 15 mg/day, range 10-40 mg)
Trial: 14700556
Drug: GH receptor
RxNorm normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH receptor blockade (not specified)
Trial: 9413377
Drug: Conventional anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional anticoagulation treatment (medical group)
Trial: 8435902
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose FSH (37.5 units daily, increased in 37.5 unit increments)
Trial: 8435902
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose FSH (75 units daily, increased in 75 unit increments)
Trial: 3630923
Drug: Nadolol (0.01,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (0.01, 0.02, and 0.04 mg/kg, maximum total dosage 10 mg)
Trial: 29264967
Drug: Probiotic tablets
RxNorm normalized name: Rezyst Probiotic
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic tablets containing Lactobacillus rhamnosus PB01, DSM 14869 and Lactobacillus curvatus EB10, DSM 32307
Trial: 31501124
Drug: Probiotic tablets
RxNorm normalized name: Rezyst Probiotic
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic tablets
Trial: 20551849
Drug: Calcium/vitamin D
RxNorm normalized name: CALCIUM/VITAMIN D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium/vitamin D supplementation (1,000 mg of elemental calcium daily plus 400 IU of vitamin D3 daily)
Trial: 16894619
Drug: Paroxetine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (40 mg/day)
Trial: 16188206
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation (4.5 g.d(‐1))
Trial: 12651679
Drug: Ropivacaine 0.15%
RxNorm normalized name: ROPivacaine 0.15%-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.15% plus 0.5 microg/mL of sufentanil
Trial: 12651679
Drug: Ropivacaine 0.10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.10% plus 0.5 microg/mL of sufentanil
Trial: 10765964
Drug: Chlorhexidine (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine (n = 30); varnish treatments at 6, 12, and 18 months after delivery.
Trial: 10765964
Drug: Fluoride (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride (n = 33); varnish treatments at 6, 12, and 18 months after delivery.
Trial: 1578942
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy with additional allogeneic bone marrow transplantation
Trial: 1578942
Drug: Stopping therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopping therapy
Trial: 3948357
Drug: Propranolol 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 180 or 240 mg daily
Trial: 31892636
Drug: IV thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV thrombolysis (alteplase 0.9 mg/kg)
Trial: 27881914
Drug: Cocoa intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa intake once daily (17 g, except Sundays) for 12 weeks
Trial: 27881914
Drug: Cocoa intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa intake twice daily every other day (17 g) for 12 weeks
Trial: 21496065
Drug: Warfarin 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin 25 mg co-administered with fesoterodine 8 mg
Trial: 22727611
Drug: Warfarin 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin 25 mg alone
Trial: 17196454
Drug: Ranolazine (extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine (extended-release formulation in MARISA, CARISA, ERICA; immediate release in RAN080)
Trial: 15071489
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nifedipine monotherapy
Trial: 2687956
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality treatment with radiotherapy and chemotherapy
Trial: 3354256
Drug: Purified inactivated
RxNorm normalized name: Purified inactivated SARS-CoV-2 Vaccine
DrugBank: BBIBP-CorV (DB15807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified inactivated rabies vaccine (PVRV), 0.5 ml, administered on days 0, 7, and 21 (Group IA)
Trial: 3354256
Drug: Purified inactivated
RxNorm normalized name: Purified inactivated SARS-CoV-2 Vaccine
DrugBank: BBIBP-CorV (DB15807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified inactivated rabies vaccine (PVRV), 0.5 ml, administered on days 0, 28, and 56 (Group IB)
Trial: 3354256
Drug: Purified inactivated
RxNorm normalized name: Purified inactivated SARS-CoV-2 Vaccine
DrugBank: BBIBP-CorV (DB15807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified inactivated rabies vaccine (PVRV), 0.5 ml, administered on days 0, 3, 7, 14, 28, and 90 (Group II)
Trial: 3354256
Drug: Purified inactivated
RxNorm normalized name: Purified inactivated SARS-CoV-2 Vaccine
DrugBank: BBIBP-CorV (DB15807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified inactivated rabies vaccine (PVRV), 0.5 ml, single booster for previously immunized individuals (Group III)
Trial: 31221722
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin (BoNT) treatment
Trial: 31221722
Drug: Open-label phase
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label phase with BoNT treatment
Trial: 18560537
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (0.5 mg)
Trial: 18560537
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (2 mg)
Trial: 18560537
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (0.5 mg and 2 mg)
Trial: 15953905
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid 500/125 mg 3 times a day for 4 days
Trial: 9801110
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 0.05% PGE1 in liposomal formulations
Trial: 683118
Drug: Fe++ sulfate
RxNorm normalized name: ferrous sulfate Extended Release Oral Tablet [Slow-Fe]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fe++ sulfate in a weak gelatine capsule (A)
Trial: 683118
Drug: Preparation B
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation B (commercial preparation)
Trial: 683118
Drug: Preparation C
RxNorm normalized name: other nasal preparation combinations in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation C (commercial preparation)
Trial: 30380357
Drug: Fiber-multivitamin combination
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber-multivitamin combination product (treatment group, n=20)
Trial: 27464321
Drug: Swedish massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swedish massage therapy (SMT)
Trial: 27097823
Drug: Doublebase™ gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doublebase™ gel (2 fingertip units, twice daily for 4 weeks)
Trial: 27097823
Drug: Diprobase® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diprobase® cream (2 fingertip units, twice daily for 4 weeks)
Trial: 20805984
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g dried broccoli sprouts for 4 weeks
Trial: 12212215
Drug: Puerarin 400
RxNorm normalized name: PUERARIA MIRIFICA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puerarin 400 mg.d-1 for 10 days
Trial: 12212215
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment (inotropic agents, diuretic, vasodilator)
Trial: 1868860
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment (10 units of standard insulin)
Trial: 3935405
Drug: Insulin-placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-placebo treatment
Trial: 24924851
Drug: Intermittent theta
RxNorm normalized name: Coptis teeta root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent theta burst stimulation (iTBS) as add-on to cognitive-behavioral therapy (CBT)
Trial: 15886753
Drug: SST-A octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SST-A octreotide with adjuvant treatment (Group B)
Trial: 12585097
Drug: Cordyceps powder
RxNorm normalized name: CORDYCEPS SINENSIS
DrugBank: Ophiocordyceps sinensis (DB19288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cordyceps powder 2‐4 g/d before meal and artemisinin 0.6 g/d after meal for 3 years
Trial: 12585097
Drug: Tripterygiitotorum and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygiitotorum and/or Baoshenkang tablet
Trial: 9583842
Drug: B‐group vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B‐group vitamins alone (1 mg folic acid, 7.2 mg pyridoxine, and 0.02 mg cyanocobalamin)
Trial: 9583842
Drug: Antioxidant vitamins
RxNorm normalized name: antioxidant vitamins with minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant vitamins alone (150 mg ascorbic acid, 67 mg RRR‐alpha‐tocopherol, and 9 mg beta‐carotene)
Trial: 8562173
Drug: FA 200
RxNorm normalized name: INPEFA 200mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FA 200 mg/m2 i.v. plus 5‐FU 400 mg/m2 i.v. on days 1‐5 every 3 weeks
Trial: 8562173
Drug: 5‐FU 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU 400 mg/m2 i.v. on days 1‐5 every 4 weeks
Trial: 2766421
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine and Western Medicine (TCM-WM)
Trial: 14714362
Drug: Western Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western Medicine (Control)
Trial: 656890
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cefuroxime intramuscularly and 1 g probenecid orally
Trial: 656890
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g cefuroxime intramuscularly with 1 g probenecid orally
Trial: 31400480
Drug: High-Intensity Interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Interval Training (HIIT) with Hormone Therapy (HT)
Trial: 21348577
Drug: Visuomotor-imagery therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visuomotor-imagery therapy
Trial: 21348577
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no supplementary therapy)
Trial: 7862833
Drug: Drink containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drink containing 50 g glucose
Trial: 30529883
Drug: 20 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g/d of high-cocoa chocolate for 4 weeks
Trial: 29908991
Drug: MAGE-A3 immunotherapeutic
RxNorm normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAGE-A3 immunotherapeutic (300 μg MAGE-A3 antigen plus 420 μg CpG 7909 reconstituted in AS01B, administered via intramuscular injections, up to 13 doses over 27 months)
Trial: 29908991
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered via intramuscular injections, up to 13 doses over 27 months)
Trial: 25397819
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU, n=21)
Trial: 11004260
Drug: Immune recovery
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune recovery uveitis patients undergoing highly active antiretroviral therapy
Trial: 1627418
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg/day for 1 year
Trial: 3676232
Drug: Low-energy diet
RxNorm normalized name: Low-energy diets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy diet with egg supplementation (two whole eggs and two egg yolks daily)
Trial: 23930204
Drug: Bevacizumab (B)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (B) in combination with capecitabine (C) and mitomycin C (M)
Trial: 16557041
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (AA)
Trial: 16557041
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (AA) + mood stabilizers
Trial: 2526933
Drug: Carbidopa (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa (100 mg x 2)
Trial: 2526933
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate (1000 mg, 11 h prior to study)
Trial: 27116023
Drug: Opioid dosing
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid dosing (morphine and oxycodone)
Trial: 24618401
Drug: Weekly application
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly application of dehydrated human amnion/chorion membrane allograft
Trial: 21095282
Drug: Highest uric
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest uric acid quartile (>10.4 mg/dL)
Trial: 14705265
Drug: Tamoxifen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen therapy over five years
Trial: 14705265
Drug: Tamoxifen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen therapy with permanent reduction in breast cancer incidence
Trial: 14705265
Drug: Tamoxifen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen therapy with further treatment effects preventing new breast cancers for up to 10 years
Trial: 14705265
Drug: Tamoxifen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen therapy with delayed breast cancer incidence
Trial: 2203218
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol and 2% or 4% pilocarpine combination eye drops
Trial: 2901270
Drug: Pancuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.1 mg kg‐1
Trial: 7387807
Drug: Suxamethonium 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium 1.0 mg kg‐1 followed by pancuronium 0.05 mg kg‐1
Trial: 29981569
Drug: Intravenous amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amino acid solution
Trial: 29981569
Drug: Intravenous dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dextrose solution
Trial: 17315084
Drug: Milk supplement
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk supplement
Trial: 24653653
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors and lifestyle modification
Trial: 19688297
Drug: Imatinib in
RxNorm normalized name: Product containing imatinib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib in combination with hydroxyurea (HU)
Trial: 19688297
Drug: Hydroxyurea (HU)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HU) monotherapy
Trial: 18625672
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (CRP) level > 3.0 mg/L
Trial: 15645268
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (IVM) - 3 mg i.v. morphine after spinal anesthesia
Trial: 15645268
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (ITM) - 0.3 mg morphine with bupivacaine during spinal anesthesia
Trial: 15645268
Drug: Intra-articular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular morphine (IAM) - 3 mg intra-articular morphine diluted in 10 ml saline before surgery
Trial: 15645268
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C) - no additional drugs
Trial: 11788624
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg mifepristone daily for 120 days
Trial: 11788624
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg mifepristone daily for 120 days
Trial: 11788624
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg mifepristone daily for 120 days (Shanghai)
Trial: 11788624
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg mifepristone daily for 120 days (Shanghai)
Trial: 12895329
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of mifepristone
Trial: 8192116
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ondansetron and dexamethasone
Trial: 3245859
Drug: 0.1% betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% betamethasone 17‐valerate cream
Trial: 1778534
Drug: 0.25% prednicarbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% prednicarbate cream
Trial: 1678236
Drug: Vehicle of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of 0.25% prednicarbate cream
Trial: 6124991
Drug: TEM 15
RxNorm normalized name: DENDROPANAX DENTIGER ROOT WITH STEM 15 g in 100 mL TOPICAL CREAM [CURICIN PFcream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEM 15 mg
Trial: 6124991
Drug: TEM 30
RxNorm normalized name: TUR System 30"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEM 30 mg
Trial: 6124991
Drug: MPD +
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MPD + TEM 15 mg
Trial: 6124991
Drug: MPD +
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MPD + TEM 30 mg
Trial: 6124991
Drug: CAF +
RxNorm normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAF + TEM 15 mg
Trial: 6124991
Drug: CAF +
RxNorm normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAF + TEM 30 mg
Trial: 6124991
Drug: CAF (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF (150 mg)
Trial: 6124991
Drug: MPD (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPD (10 mg)
Trial: 20937606
Drug: telcagepant 300
RxNorm normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telcagepant 300 mg
Trial: 20078608
Drug: telcagepant 800
RxNorm normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telcagepant 800 mg
Trial: 17587399
Drug: 2 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg/day (maximum 200 mg/day) of oral diazoxide
Trial: 16258098
Drug: Antibiotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics plus G-CSF (ciprofloxacin and roxithromycin with G-CSF on days 4 to 13)
Trial: 16258098
Drug: Antibiotics alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics alone (ciprofloxacin and roxithromycin)